For the year ending 2025-12-31, MLTX has $424,433K in assets. $119,952K in debts. $334,517K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 334,517 | |||
| Short-term marketable debt securities | 59,451 | |||
| Other receivables | 4,869 | |||
| Prepaid expenses | 22,857 | |||
| Total current assets | 421,694 | |||
| Operating lease right-of-use assets | 1,566 | |||
| Property and equipment, net | 577 | |||
| Other non-current assets | 596 | |||
| Total non-current assets | 2,739 | |||
| Total assets | 424,433 | |||
| Trade and other payables | 29,553 | |||
| Accrued expenses and other current liabilities | 14,691 | |||
| Short-term portion of operating lease liabilities | 1,234 | |||
| Total current liabilities | 45,478 | |||
| Long-term debt | 74,100 | |||
| Long-term portion of operating lease liabilities | 374 | |||
| Pension liability | 0 | |||
| Total non-current liabilities | 74,474 | |||
| Total liabilities | 119,952 | |||
| Common shares-Common Class A | 7 | |||
| Common shares-Common Class C | 0 | |||
| Additional paid-in capital | 766,781 | |||
| Accumulated deficit | -462,911 | |||
| Accumulated other comprehensive income | 604 | |||
| Total shareholders equity | 304,481 | |||
| Noncontrolling interests | 0 | |||
| Total equity | 304,481 | |||
| Total liabilities and equity | 424,433 | |||
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)